E-therapeutics Regulatory News (ETX)

e-Therapeutics plc

('e-Therapeutics' or 'the Company') 

Notification of Full Year Results Date

Oxford and Newcastle, UK - 10 March 2015 - e-Therapeutics plc (AIM: ETX), the drug discovery and development company, will announce its full year results for the period ended 31 January 2015 on Tuesday, 31 March 2015.

A group analyst briefing will be held at 11:30am on Tuesday, 31 March 2015 at Instinctif Partners' offices at 65 Gresham Street, London EC2V 7NQ.

Analysts who wish to participate should contact Instinctif Partners on +44 (0)20 7457 2020 or email

e-therapeutics@instinctif.com to register.

-Ends-

Contacts:

e-Therapeutics plc

Steve Medlicott

Tel: +44 (0) 1993 883125

www.etherapeutics.co.uk 

N+1 Singer

Aubrey Powell / Jen Boorer

Tel: +44 (0)20 7496 3000

www.n1singer.com 

Instinctif Partners

Melanie Toyne-Sewell / Emma Barlow

Tel: +44 (0) 20 7457 2020

Email: e-therapeutics@instinctif.com

About e-Therapeutics plc

e-Therapeutics is an AIM-quoted drug discovery and development company with a proprietary platform in network pharmacology, an innovative new approach to drug discovery based on advances in network science and chemical biology. The Company's discovery and development activity is currently focused in cancer and disorders of the nervous system.

e-Therapeutics is based at sites in Oxford and Newcastle, UK. For more information about the Company, please visit www.etherapeutics.co.uk.